Disclosed are compounds, having the following structure, useful as inhibitors of Phosphodiesterase 1 (PDE1), compositions comprising the compounds, and methods of using the same.
The present invention provides a substituted pyrrolidine compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I):
wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
Pharmaceutical compositions for prevention and treatment of central
申请人:——
公开号:US05726316A1
公开(公告)日:1998-03-10
Patients susceptible to or suffering from central nervous system disorders are treated by administering an effective amount of an aryl substituted olefinic amine compound or an aryl substituted acetylenic compound. Exemplary compounds are (E)-N-methyl-4-\x9b3-(6-methylpyrindin)yl!-3-butene-1-amine and N-methyl-4-(3-pyridinyl)-3-butyne-1-amine.
HETEROARYL DERIVATIVE, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE COMPONENT
申请人:Voronoi Inc.
公开号:EP3943491A1
公开(公告)日:2022-01-26
The present invention relates to a 6-(isooxazolidin-2-yl)-N-phenylpyrimidin-4-amine derivative, and a pharmaceutical composition for preventing or treating cancer comprising the compound as an effective component. The compound exhibits high inhibitory activity against an epidermal growth factor receptor (EGFR) variant, or wild-type or variants of one or more of ERBB2 and ERBB4, and thus may be usefully used in the treatment of cancers in which same are expressed. In particular, the compound exhibits excellent inhibitory activity on proliferation of lung cancer cell lines, and can thus be usefully used in the treatment of lung cancer.